País: Estados Unidos
Língua: inglês
Origem: NLM (National Library of Medicine)
AMLODIPINE BESYLATE (UNII: 864V2Q084H) (AMLODIPINE - UNII:1J444QC288), OLMESARTAN MEDOXOMIL (UNII: 6M97XTV3HD) (OLMESARTAN - UNII:8W1IQP3U10)
Daiichi Sankyo Inc.
AMLODIPINE BESYLATE
AMLODIPINE 5 mg
ORAL
PRESCRIPTION DRUG
Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Ev
Azor tablets contain amlodipine besylate at a dose equivalent to 5 or 10 mg amlodipine and olmesartan medoxomil in the strengths described below. Azor tablets are differentiated by tablet color/size and are debossed with an individual product tablet code on one side. Azor tablets are supplied for oral administration in the following strength and package configurations: Store at 25ºC (77ºF); excursions permitted to 15ºC-30ºC (59ºF-86ºF) [see USP Controlled Room Temperature] .
New Drug Application
AZOR- AMLODIPINE BESYLATE AND OLMESARTAN MEDOXOMIL TABLET, FILM COATED DAIICHI SANKYO INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE AZOR SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR AZOR. AZOR (AMLODIPINE AND OLMESARTAN MEDOXOMIL) TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2007 WARNING: FETAL TOXICITY _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ WHEN PREGNANCY IS DETECTED, DISCONTINUE AZOR AS SOON AS POSSIBLE (5.1, 8.1). DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE INJURY AND DEATH TO THE DEVELOPING FETUS (5.1, 8.1). INDICATIONS AND USAGE Azor is a combination of amlodipine besylate, a dihydropyridine calcium channel blocker, and olmesartan medoxomil, an angiotensin II receptor blocker, indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1). Azor may also be used as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals (1). DOSAGE AND ADMINISTRATION Recommended starting dose: 5/20 mg once daily (2). Titrate as needed in two-week intervals up to a maximum of 10/40 mg once daily (2). DOSAGE FORMS AND STRENGTHS Tablets: (amlodipine/olmesartan medoxomil content) 5/20 mg, 10/20 mg, 5/40 mg, and 10/40 mg (3). CONTRAINDICATIONS Do not co-administer aliskiren with Azor in patients with diabetes (4). WARNINGS AND PRECAUTIONS Anticipate hypotension in volume- or salt-depleted patients with treatment initiation. Start treatment under close supervision (5.2). Increased angina or myocardial infarction may occur upon dosage initiation or increase (5.3). Impaired renal function: changes in renal function may occur (5.4). Sprue-like enteropathy has been reported. Consider discontinuation of Azor in cases where no other etiology is found (5.6). ADVERS Leia o documento completo